Aurinia Pharmaceuticals Revenue

Biotechnology Research • Edmonton, Alberta, Canada • 101-200 Employees

Aurinia Pharmaceuticals revenue & valuation

Annual revenue	$260,200,000
Revenue per employee	$1,567,000
Estimated valuation?This valuation is estimated based on industry average for the Biotechnology Research industry and current estimated revenues	$832,400,000
Total funding	$200,000,000

Key Contacts at Aurinia Pharmaceuticals

Schuyler Rose

Director Of Marketing, Peer To Peer, Kol Engagement

William Hatcher

Director Of Quality Control

Henry Leher

Executive Medical Director

Bradley Parent

Senior Director, Contracts, Payor Access Operations And Corporate Accounts

Ron Flauto

Senior Medical Director / Medical Director

Christopher Kakidas

Director, Drug Product Development

Doodie Crocker

Senior Corporate Account Director

Jonathan Arena

Executive Director, Commercial Excellence

Andrea Levin Christopher

Executive Director, Corporate Communications & Investor Relations

Darrell Mcclure

Director, Head Of It Operations

Company overview

Headquarters	Edmonton, Alberta, Canada
Phone number	+1230010508
Website	auriniapharma.com
NAICS	541714
SIC	283
Keywords	Biotechnology, Rheumatology, Nephrology, Drug Development, Immunology, Autoimmune, Lupus Nephritis
Founded	2013
Employees	101-200
Socials

Aurinia Pharmaceuticals Email Formats

Aurinia Pharmaceuticals uses 3 email formats. The most common is {first initial}{last name} (e.g., jdoe@auriniapharma.com), used 65.4% of the time.

Format	Example	Percentage
{first initial}{last name}	jdoe@auriniapharma.com	65.4%
{first name}{last name}	johndoe@auriniapharma.com	27.1%
{last name}{last name}	doedoe@auriniapharma.com	4.5%

About Aurinia Pharmaceuticals

Aurinia is a biopharmaceutical company focused on delivering therapies to people living with autoimmune diseases with high unmet medical needs. In January 2021, the Company introduced LUPKYNIS® (voclosporin), the first FDA-approved oral therapy for the treatment of adult patients with active lupus nephritis. Aurinia is also developing AUR200, a dual inhibitor of B cell activating factor (BAFF) and a proliferation inducing ligand (APRIL) for the potential treatment of autoimmune diseases. Community guidelines: 1. By posting to our social media channels, or otherwise responding or commenting on our posts, you are agreeing to abide by these guidelines, which apply in addition to any terms and conditions or other notices or disclaimers that we may apply, or that may be applied by the host of the social media platform itself. 2. Unless posts are from an official Aurinia social media handle, none of the posts or comments are posts made by us, but from members of the public. We take no responsibility for comments or posts made by third parties on our channels, and the content of those comments or posts (including any opinions or statements) may not reflect our views, and are the responsibility of the individual posting them. 3. We may discuss medical and health-related topics on our social media feeds. The content we post, and any associated content shared by other users, should not be taken as medical advice. We ask that you refrain from soliciting or posting medical advice on this feed. For advice and information related to your health, please seek advice from your doctor or other healthcare professional. 4. Aurinia reserves the right to remove any content or comments that violate these guidelines or are otherwise deemed inappropriate. We may block or ban users who repeatedly violate these guidelines or engage in disruptive behavior. To learn more, visit: https://www.auriniapharma.com/aurinia-community-guidelines US-NA-2300266 08/23

Employees by Management Level

Total employees: 101-200

Seniority

Employees

Entry

Director

Manager

Employees by Department

Aurinia Pharmaceuticals has 93 employees across 12 departments.

Departments

Number of employees

Funding Data

Explore Aurinia Pharmaceuticals's funding history, including investment rounds, total capital raised, and key backers.

Funding Date	Round	Amount	Link to Article
2020-08-22	14	$200,000,000

Funding Insights

$200,000,000

Total funding amount

$200,000,000

Most recent funding amount

Number of funding rounds

Aurinia Pharmaceuticals Tech Stack

Discover the technologies and tools that power Aurinia Pharmaceuticals's digital infrastructure, from frameworks to analytics platforms.

Klaro

Cookie compliance

PWA

Miscellaneous

Microsoft 365

Apache HTTP Server

Web servers

jQuery

JavaScript libraries

Apple iCloud Mail

Webmail

HSTS

Security

Zoho

CRM

Google Analytics

Analytics

Bootstrap

UI frameworks

hCaptcha

Security

Salesforce

CRM

Frequently asked questions

Aurinia Pharmaceuticals is located in Edmonton, Alberta, CA.

You can reach Aurinia Pharmaceuticals at +1230010508.

Aurinia Pharmaceuticals generates an estimated annual revenue of $260,111,000. This revenue figure reflects the company's market position and business performance in its industry.

Aurinia Pharmaceuticals has an estimated valuation of $832,400,000. This valuation is calculated based on industry-standard revenue multiples and reflects the company's growth potential and market positioning.

Aurinia Pharmaceuticals was founded in 2013, making it 13 years old. The company has established itself as a significant player in its industry over this time.

Aurinia Pharmaceuticals has approximately 101-200 employees. The company continues to grow its workforce to support its business operations and expansion.

Aurinia Pharmaceuticals has raised a total of $200,000,000 across 1 funding rounds. This investment has helped the company grow and expand its operations.